Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850354 | 0.88 | GAA (0.49) | ALDH1A1GAAGFERABL1RIN1 | |
| SCHEMBL15861906 | 0.85 | ALDH1A1 (0.53) | ALDH1A1GAAGFERTSHRNFKB1 | |
| SCHEMBL1644709 | 0.85 | ABL1 (0.46) | ALDH1A1ABL1RIN1MEN1KMT2A | |
| SCHEMBL13941511 | 0.84 | GAA (0.49) | ALDH1A1GAAGFERABL1RIN1 | |
| SCHEMBL4837545 | 0.84 | ALDH1A1 (0.53) | ALDH1A1GAAGFERABL1RIN1 | |
| SCHEMBL22898416 | 0.83 | ALDH1A1 (0.50) | ALDH1A1GAAGFERABL1RIN1 | |
| SCHEMBL31260362 | 0.82 | ALDH1A1 (0.48) | ALDH1A1GAAGFERABL1RIN1 | |
| SCHEMBL29626821 | 0.82 | ALDH1A1 (0.62) | ALDH1A1GAAGFERABL1RIN1 | |
| SCHEMBL198282 | 0.82 | ALDH1A1 (0.62) | ALDH1A1GAAGFERABL1RIN1 | |
| SCHEMBL31236975 | 0.81 | ABL1 (0.56) | ALDH1A1GAAGFERABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2281580-A2 | Labeled gastrin releasing peptides (GRP) | Bracco Imaging S.p.A (IT) | 2011-02-09 | — | — | EP | disclosed |
| US-20090191183-A1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009018280-A2 | SUBSTITUTED INDOLES | AUSPEX PHARAMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080247946-A1 | Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2008-10-09 | — | — | US | disclosed |
| US-20070231257-A1 | Radiodiagnosis, radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191183-A1 | SUBSTITUTED INDOLES | CYSLTR1, LTB4R, LTB4R2 | ALDH1A1 717/4885GAA 3776/4885GFER 684/4885 |
| US-20070231257-A1 | Radiodiagnosis, radiotherapy | GRPR, MRGPRX2, MRGPRX1 | ALDH1A1 4443/4885GAA 1131/4885GFER 1899/4885 |
| US-20080247946-A1 | Bombesin capable of complexing with metal ions, radionuclides, or optical labels; radiotherapy | GRPR, MRGPRX1, BRS3 | ALDH1A1 4853/4885GAA 2412/4885GFER 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.